手术治疗结节性甲状腺肿合并甲状腺癌的临床效果

目的:分析手术治疗结节性甲状腺肿合并甲状腺癌的临床效果。方法:从2017年3月~2019年3月期间到我院接受治疗的结节性甲状腺肿合并甲状腺癌患者中选出60例完成此次研究,60例患者全部接受手术治疗,经1年的随访后对比两组患者接受治疗前后的生活质量变化情况及治疗效果。结果:接受治疗后患者的心理、身体、物质生活、社会关系等多项生活质量指标均优于治疗前,治疗前后的数据对比存在明显差异(P<0.05)。所有患者接受治疗后均为表现出较为明显的不良反应,其治疗存在较高安全性,总治疗有效率为87.50%(55/60)。结论:帮助结节性甲状腺肿合并甲状腺癌患者选择合理的手术方式,能够提高临床治疗效果,减少并发症。     

妊娠期疾病类型与甲状腺功能异常相关性分析

目的研究妊娠期疾病类型与甲状腺功能异常相关性。方法回顾性分析2015年1月-2017年1月期间在天津港口医院治疗的107例孕妇,根据妊娠期是否患病分为A组、B组与对照组。A组为22例确诊为妊娠期糖尿病的患者;B组为36例确诊为妊娠期高血压疾病的患者;对照组为49例妊娠期血糖与血压正常、无其他疾病的孕妇。所有研究对象妊娠期定期抽取静脉血检测甲状腺功能、血压及血糖水平。采用妊娠期高血压疾病诊断标准、妊娠期糖尿病诊断标准以及妊娠期甲状腺疾病诊断标准联合评价。结果此研究发现糖尿病组与对照组在孕中期游离T4值、A组与对照组在孕晚期、B组与对照组在孕中期和孕晚期的促甲状腺激素(TSH)值对比,差异均有统计学意义(均P<0.05);3组孕妇不同妊娠时期临床甲状腺功能亢进、减退的发病情况各组别数据对比,差异无统计学意义(P>0.05);A组、B组与对照组在孕中期与孕晚期亚临床甲状腺功能减退发病情况数据对比,A组、B组与对照组在不同妊娠时期低T4血症发病情况数据对比,差异均有统计学意义(均P<0.05);孕早期仅甲状腺过氧化物酶抗体(TPOAb)阳性与甲状腺正常数据对比,B组发生率高于对照组、A组发生率低于对照组,差异均有统计学意义(均P<0.05)。结论与正常孕妇相比,妊娠期高血压疾病与妊娠期糖尿病患者在不同妊娠期的游离T4水平更低、TSH水平更高,且随着妊娠期的增长,变化趋势不断增大;妊娠期疾病类型与甲状腺功能异常存在着联系,妊娠期高血压疾病和糖尿病患者甲状腺功能异常发病率明显更高。     

甲状旁腺激素对大鼠牵张成骨过程中O NC、OPN、C-FOS、COL1、VEGF、RUNX2、ALP基因表达的影响

目的：探讨甲状旁腺激素（PTH）对大鼠牵张成骨（DO）过程中ONC、OPN、C-FOS、COL1、VEGF、RUNX2、ALP基因表达的影响。方法30只雄性大鼠制备大鼠下颌骨DO模型。随机分5组，每组6只。第1组（只有牵张无PTH），术后8周取材，应用HE染色及微CT检测，以确定成骨情况。第2组（有牵张无PTH），第3组（有牵张有PTH），第4组（无牵张有PTH），第5组（对照组：无牵张无PTH）。2、3、4组及对照组术后1周取材，RT-PCR测定ONC、OPN、C-FOS、COL1、VEGF、RUNX2、ALP基因的表达。结果第1组，新骨形成，骨质充满牵张区，骨质连续，大鼠建模成功。RT-PCR检测结果显示，2、3、4组与对照组比较，OPN、COL1、RUNX2、ALP基因表达有明显提高（P＜0．05），其中第3组最为明显。ONC、C-FOS、VEGF基因2、3、4组与对照组比较差异无统计学意义（P＞0．05）。结论 PTH在 DO 过程中，间歇性给以 PTH的作用只有在牵张期发挥作用，其对 OPN、COL1、RUNX2、ALP基因表达能够获得理想的协同作用。     

Gender,race and socioeconomic influence on diagnosis and treatment of thyroid disorders in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)

Thyroid diseases are common, and use of levothyroxine is increasing worldwide. We investigated the influence of gender, race and socioeconomic status on the diagnosis and treatment of thyroid disorders using data from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil), a multicenter cohort study of civil servants (35-74 years of age) from six Brazilian cities. Diagnosis of thyroid dysfunction was by thyrotropin (TSH), and free thyroxine (FT4) if TSH was altered, and the use of specific medications. Multivariate logistic regression models were constructed using overt hyperthyroidism/hypothyroidism and levothyroxine use as dependent variables and sociodemographic characteristics as independent variables. The frequencies of overt hyper- and hypothyroidism were 0.7 and 7.4%, respectively. Using whites as the reference ethnicity, brown, and black race were protective for overt hypothyroidism (OR=0.76, 95%CI=0.64-0.89, and OR=0.53, 95%CI=0.43-0.67, respectively, and black race was associated with overt hyperthyroidism (OR=1.82, 95%CI=1.06-3.11). Frequency of hypothyroidism treatment was higher in women, browns, highly educated participants and those with high net family incomes. After multivariate adjustment, levothyroxine use was associated with female gender (OR=6.06, 95%CI=3.19-11.49) and high net family income (OR=3.23, 95%CI=1.02-10.23). Frequency of hyperthyroidism treatment was higher in older than in younger individuals. Sociodemographic factors strongly influenced the diagnosis and treatment of thyroid disorders, including the use of levothyroxine.     

Lack of ceramide synthase 2 suppresses the development of experimental autoimmune encephalomyelitis by impairing the migratory capacity of neutrophils

Ceramide synthases (CerS) synthesise ceramides of defined acyl chain lengths, which are thought to mediate cellular processes in a chain length-dependent manner. In experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), we observed a significant elevation of CerS2 and its products, C24-ceramides, in CD11b⁺ cells (monocytes and neutrophils) isolated from blood. This result correlates with the clinical finding that CerS2 mRNA expression and C24-ceramide levels were significantly increased by 2.2- and 1.5-fold, respectively, in white blood cells of MS patients. The increased CerS2 mRNA/C24-ceramide expression in neutrophils/monocytes seems to mediate pro-inflammatory effects, since a specific genetic deletion of CerS2 in blood cells or a total genetic deletion of CerS2 significantly delayed the onset of clinical symptoms, due to a reduced infiltration of immune cells, in particular neutrophils, into the central nervous system. CXCR2 chemokine receptors, expressed on neutrophils, promote the migration of neutrophils into the central nervous system, which is a prerequisite for the recruitment of further immune cells and the inflammatory process that leads to the development of MS. Interestingly, neutrophils isolated from CerS2 null EAE mice, as opposed to WT EAE mice, were characterised by significantly lower CXCR2 receptor mRNA expression resulting in their reduced migratory capacity towards CXCL2. Most importantly, G-CSF-induced CXCR2 expression was significantly reduced in CerS2 null neutrophils and their migratory capacity was significantly impaired. In conclusion, our data strongly indicate that G-CSF-induced CXCR2 expression is regulated in a CerS2-dependent manner and that CerS2 thereby promotes the migration of neutrophils, thus, contributing to inflammation and the development of EAE and MS.     

Could non-HDL-cholesterol be a better marker of atherogenic dyslipidemia in obstructive sleep apnea?

Background/objectiveObstructive sleep apnea (OSA) is independently associated with dyslipidemia, a surrogate marker of atherosclerosis. Low-density lipoprotein (LDL)-cholesterol is accepted as a major independent risk factor for cardiovascular disease. However, non-high-density lipoprotein (HDL)-cholesterol is a better marker of atherogenic dyslipidemia and recommended as a target of lipid lowering therapy. We aimed to assess the prevalence of atherogenic dyslipidemia, and relationship between OSA severity and serum LDL-cholesterol and non-HDL cholesterol levels in OSA patients.MethodsWe retrospectively evaluated treatment naïve 2361 subjects admitted to the sleep laboratory of a university hospital for polysomnography. All subjects’ lipid profile including total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, and non-HDL-cholesterol were measured.ResultsOut of 2361 patients (mean age 49.6 ± 11.9 years; 68.9% male, apnea-hypopnea index 36.6 ± 28.4/h), 185 (7.8%) had no OSA and 2176 (92.2%) had OSA. Atherogenic dyslipidemia prevalence was high (57–66%) in OSA patients, and especially increased in severe OSA compared to other groups (p < 0.05). Though total and LDL-cholesterol did not differ between those with and without OSA, non-HDL-cholesterol (p = 0.020), and triglycerides (p = 0.001) were higher and HDL-cholesterol levels (p = 0.018) were lower in OSA patients than non-OSA. Non-HDL-cholesterol was significantly correlated with OSA severity (p < 0.001) and hypoxia parameters (p < 0.01), whereas LDL-cholesterol showed no correlation.ConclusionsAtherogenic dyslipidemia is highly prevalent and non-HDL-cholesterol levels are significantly increased, predominantly in severe OSA patients. Non-HDL-cholesterol but not LDL-cholesterol, is significantly correlated with OSA severity and hypoxia parameters. Therefore, it could be better to use non-HDL-cholesterol, which is a guideline recommended target of lipid therapy, as a marker of atherosclerotic cardiovascular risk in OSA patients.